Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 92%
filed 2026-06-09
Item 3.02
The filing discloses two unregistered equity issuances: (1) 398,666 shares issued as consideration for the Lyphe Group acquisition under Section 4(a)(2), and (2) 1,214,186 shares issued in a debt-for-equity exchange under Section 3(a)(9). Together, these represent approximately 1.6 million shares of dilutive issuance, with the debt exchange alone converting $6 million of convertible notes. This is material to investors as it increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-09
Item 8.01
Allegiant Travel announced a private offering of $650.0 million in Senior Secured Notes due 2031, increased from the previously announced $500.0 million. The offering is being conducted under Rule 144A and Regulation S as an unregistered private placement to qualified institutional buyers and non-U.S. persons. While technically debt rather than equity, this represents a material capital-raising transaction that increases the company's financial obligations and would affect a reasonable investor's assessment of leverage and financial structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-09
Item 7.01
The company announced the immediate departure of two senior executives: Greg Dale (Chief Operating Officer) and Frank Friedman (Head of Measurement and Chief Data and Analytics Officer). Their responsibilities are being assumed by the CEO.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-09
Item 8.01
The filing discloses a press release issued on June 9, 2026, but the actual content of the press release is not provided in the Item 8.01 text itself—only a reference to Exhibit 99.1. Without access to the exhibit content, the specific nature of the material event cannot be determined. Given that it is disclosed under Item 8.01 (Other Events) and involves a press release, it is likely material, but the event type cannot be confidently classified into a more specific category (e.g., earnings_release, material_litigation, going_concern) without knowing the press release's subject matter.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-09
Item 8.01
The filing discloses a press release issued on June 9, 2026, but the actual content of the press release is not provided in the Item 8.01 text itself—only a reference to Exhibit 99.1. Without access to the exhibit content, the specific nature of the announcement cannot be determined. Given the Item 8.01 classification (Other Events) and the presence of a press release, this is likely material, but the event type cannot be confidently assigned to a more specific category without knowing what the press release announces.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-09
Item 8.01
The filing discloses updated risk factors relating to the Company's expansion into GPU computing infrastructure ownership and operation. While Item 8.01 is used for miscellaneous disclosures, the explicit statement that updated risk factors "supersede" prior disclosures and the material nature of the business expansion (GPU data center infrastructure) suggest this is a material event that does not fit neatly into more specific categories. The disclosure appears designed to inform investors of newly material risks associated with a significant business line expansion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-06-09
Item 1.01
Novanta Inc. entered into an Equity Purchase Agreement on June 8, 2026, to acquire all issued and outstanding interests of Runway Buyer for $1.2 billion in closing consideration plus a $250 million milestone payment, subject to HSR approval and other regulatory conditions. The transaction was announced via press release on June 9, 2026, with forward-looking statements addressing expected timing, completion, anticipated synergies, and integration risks.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-09
Item 2.02
Lands' End disclosed financial results for the first quarter ended May 1, 2026, furnished as a press release exhibit. This is a standard quarterly earnings announcement.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-06-09
Item 1.01
Nuvalent entered into an Agreement and Plan of Merger with GlaxoSmithKline LLC on June 9, 2026, whereby GSK will commence a tender offer at $124.00 per share, followed by a merger if conditions are satisfied. This is a material acquisition and change of control transaction.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-09
Item 8.01
The filing discloses a press release reporting AUM as of May 31, 2026, filed under Item 8.01 (Other Events). While AUM is a key operational metric for asset management firms, this disclosure does not fit the standard earnings_release category (which typically reports quarterly or annual financial results with comprehensive income statement and balance sheet data). The filing appears to be a standalone AUM update rather than a full earnings release, making other_material the most appropriate classification, though the materiality depends on whether the AUM figures represent significant changes that would affect investor assessment of the company's business performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-06-09
Item 8.01
This Item 8.01 disclosure presents Mercury General's consolidated financial highlights for Q1 2026 and full-year 2025, including net premiums earned, net income, and operating income figures. The filing includes detailed financial tables comparing Q1 2026 to Q1 2025 and full-year 2025 to 2024, along with reconciliations to GAAP measures. This constitutes a material earnings disclosure that would affect investor assessment of the company's financial performance and operational trends.
View raw filing on EDGAR →
8-K
Cybersecurity Incident
confidence 95%
filed 2026-06-09
Item 8.01
The filing discloses a material cybersecurity incident at Evertec, a third-party core processing provider, affecting customer data of BPPR (Popular's Puerto Rico subsidiary). The compromised data includes personal information, debit card numbers, and other customer information. Although the Corporation states it does not currently believe the incident is reasonably likely to have material impact, the disclosure itself—involving customer data compromise, regulatory notification, and enhanced fraud monitoring—constitutes a material cybersecurity incident requiring 8-K disclosure under Item 1.05 rules (effective 2023).
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-09
Item 2.03
This Item 2.03 disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While the filing explicitly states "consolidated obligations issuance is material to the FHLBank," the disclosure is primarily informational and regulatory in nature—describing the mechanics of consolidated obligation issuance, the joint and several liability structure, and the exclusions from Schedule A. The filing does not disclose a specific new debt covenant, acceleration clause, or cross-default trigger that would constitute a "covenant_breach" event. The materiality lies in the ongoing debt issuance program rather than a discrete triggering event, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-09
Item 1.01
Sherwin-Williams entered into Amendment No. 11 to its credit facility, extending $200 million in credit commitments from June 2026 to June 2031. This material financing arrangement affects the company's liquidity and capital structure flexibility.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-09
Item 7.01
The filing discloses an updated 2026 outlook following the acquisition of Thermon Group Holdings, Inc., issued via press release on June 9, 2026. While the acquisition itself would typically be classified as ma_activity, this Item 7.01 disclosure focuses on the forward guidance update rather than the acquisition event itself. The guidance update is material to investors assessing future performance, but the disclosure is furnished (not filed) under Regulation FD, and the core acquisition event likely appears elsewhere in the 8-K. This is best classified as other_material since it is a material forward-looking statement tied to a completed acquisition, but does not fit neatly into earnings_release (no historical results) or the ma_activity category (the acquisition is referenced as context, not as the primary disclosed event).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder vote results from the June 4, 2026 annual meeting of stockholders. The filing reports the final voting tallies for two proposals: (1) election of Wendell E. Pritchett as a Class III director with 18,436,266 votes for and zero against, and (2) ratification of Deloitte & Touche LLP as independent auditor with identical voting results. This is a routine but material Item 5.07 disclosure required by SEC rules for annual meeting outcomes.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-09
Item 1.01
PennantPark Private Income Fund entered into a second amendment to its senior secured revolving credit facility on June 5, 2026, increasing borrowing capacity from $120.0 million to $200.0 million. While this is a credit facility amendment rather than a traditional M&A transaction, it represents a material change to the registrant's financing structure and debt capacity, which would affect a reasonable investor's assessment of the company's liquidity and financial flexibility. The 67% increase in available borrowing capacity is a material financial event disclosed under Item 1.01.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Verrica Pharmaceuticals held an Annual Meeting of Stockholders with four proposals: election of directors, advisory approval of named executive officer compensation, ratification of KPMG LLP as auditor, and approval of the Amended and Restated 2018 Equity Incentive Plan. Vote results for all four proposals are disclosed with detailed tallies.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Shareholders voted at the June 3, 2026 Annual Meeting, approving four proposals: election of directors Donna Corley and Tela Mathias as Class II directors, ratification of Deloitte as independent auditor, advisory approval of named executive officer compensation, and approval of a reverse stock split amendment.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-09
Item 5.03
The company effected a 1-for-10 reverse stock split of Class A common stock via a Certificate of Amendment to the Certificate of Incorporation filed with Delaware on June 8, 2026, with trading on a split-adjusted basis commencing June 9, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the final results of the Company's 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing presents voting tallies for two proposals: election of three Class I directors (Robert A. Lenz, Rebecca Luse, and Ran Nussbaum) and ratification of BDO USA, P.C. as independent auditor. All proposals passed with substantial majorities. Shareholder vote results are material to investors as they confirm board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-09
Item 8.01
This Item 8.01 disclosure concerns a prospectus supplement amendment registering additional resale shares (39,843 shares) issued as consideration in the Company's acquisition of Brex Inc., which closed April 7, 2026. While the underlying M&A transaction is material, this specific filing is a routine registration statement amendment for resale of acquisition consideration shares—a procedural capital markets disclosure rather than a new material event. The acquisition itself would have been disclosed in a prior 8-K; this filing merely updates the resale registration mechanics.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Stifel Financial Corp. held its Annual Meeting of Shareholders on June 9, 2026, with shareholders voting on five proposals: election of twelve directors, advisory vote on named executive officer compensation, amendment to the Certificate of Incorporation to increase authorized shares from 197 million to 294 million total shares and from 194 million to 291 million common shares, amendment to the 2001 Incentive Stock Plan to increase share capacity by 9,000,000 shares, and ratification of KPMG LLP as independent auditor. All proposals were approved with detailed voting tallies disclosed.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-09
Item 1.01
Getaround completed the sale of its entire European business to GoMore ApS for approximately €31.5 million plus contingent consideration, effective April 30, 2026, as part of the Company's orderly wind-down strategy. The transaction included a significant debt restructuring with Mudrick Capital involving cancellation of approximately $121.7 million in senior secured indebtedness and issuance of a super priority secured promissory note.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-09
Item 8.01
On June 5, 2026, the Board determined that voluntary dissolution of the Company under Delaware General Corporation Law Section 275 et seq. is in the best interests of the Company and its residual claimants, requiring stockholder approval.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-09
Item 5.02
Aaron M. Kale was appointed as Chief Accounting Officer (principal accounting officer) effective June 8, 2026, following Suzanne M. Thuerk's resignation notice on June 4, 2026. While the disclosure includes both a departure and an appointment, the principal disclosed action centers on the appointment of Kale to the principal accounting officer role, a material executive position. The filing emphasizes Kale's qualifications and transition support, making the appointment the salient event.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-09
Item 8.01
Sempra closed a $1 billion public offering of floating-rate notes due 2028, netting approximately $998.5 million in proceeds. While this is a material capital-raising event affecting the company's financial position and liquidity, it does not fit cleanly into the standard 8-K taxonomy—it is neither a debt covenant breach, a dilutive equity issuance, nor an M&A transaction. The disclosure is material to investors as it represents a significant debt financing, but the absence of a more specific category warrants classification as other_material.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-09
Item 2.02
Lakeland Industries disclosed financial results for the first quarter ended April 30, 2026, via press release filed under Item 2.02, with supplemental slides for an earnings call scheduled for June 9, 2026.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-09
Item 8.01
Wolfspeed disclosed unaudited pro forma financial information reflecting the effects of its prepackaged Chapter 11 plan of reorganization (effective September 29, 2025), fresh start accounting under ASC 852, and receipt of regulatory approvals (January 29, 2026). While the bankruptcy filing itself would have been disclosed as a bankruptcy_filing event, this Item 8.01 disclosure is a post-emergence update providing pro forma financials to investors. This is material to investors assessing the company's financial position post-reorganization, but does not fit neatly into the more specific event categories (the bankruptcy occurred in 2025; this is a 2026 informational update). The disclosure is substantive and would affect a reasonable investor's understanding of the company's financial condition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-09
Item 8.01
Hubbell Inc. completed its acquisition of NSI Industries, a provider of electrical fittings, connectors, components, and wire management products, on June 9, 2026. The completion of this material acquisition was disclosed via press release and represents a significant strategic expansion of the registrant's business scope.
View raw filing on EDGAR →
8-K
Other material
confidence 73%
filed 2026-06-09
Item 8.01
Shattuck Labs announced Phase 1 clinical trial data for its lead DR3 blocking antibody SL-325, demonstrating favorable safety, tolerability, and pharmacokinetic results with low immunogenicity (3.7% ADA rate). The company outlined material clinical milestones including initiation of Phase 2b trial (RECEPTIVE-CD1) in Q3 2026 and an IND filing for SL-846 in H1 2027, while simultaneously raising approximately $54.9 million in gross proceeds through warrant exercises (96% of outstanding warrants from August 2025 private placement).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Interactive Strength's June 8, 2026 annual meeting of stockholders. The filing presents voting outcomes for eight proposals, including director elections (Trent A. Ward and Kirsten Bartok Touw), ratification of Deloitte & Touche LLP as auditor, approval of dilutive issuances related to Wattbike and Ergatta acquisitions, stock plan amendments, reverse stock split authority, and advisory votes on executive compensation. The disclosure of shareholder vote results is material as it confirms stockholder approval of significant corporate actions including M&A-related equity issuances and governance matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder voting results from the June 5, 2026 Annual Meeting of Stockholders, covering three proposals: election of directors, ratification of the independent auditor (KPMG LLP), and an advisory vote on named executive officer compensation. The filing presents final vote tallies for each proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a clear disclosure of shareholder voting results from Adaptive Biotechnologies' June 5, 2026 annual meeting, covering three proposals: election of two Class I directors (Hershberg and Owen), advisory vote on 2025 named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The detailed voting tallies and percentages match the shareholder_vote_results taxonomy precisely, and the results are material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-09
Item 1.01
Affiliated Managers Group entered into a Fourth Amended and Restated Credit Agreement on June 9, 2026, establishing a $1.25 billion senior unsecured multicurrency revolving credit facility maturing in 2031, with an option to increase commitments by up to $750 million. This refinancing and amendment of the existing credit facility constitutes a material definitive agreement affecting the Company's capital structure and financial flexibility.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-09
Item 1.01
Cheniere Partners closed a $1.75 billion private placement of senior notes on June 9, 2026, consisting of $1 billion 2036 Notes and $750 million 2056 Notes, pursuant to supplemental indentures. This material debt financing activity affects the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Relay Therapeutics held its 2026 Annual Meeting of Stockholders, at which shareholders voted on and approved four proposals: election of class III directors Douglas S. Ingram and Claire Mazumdar, Ph.D.; a non-binding advisory vote on executive compensation; ratification of Ernst & Young LLP as independent auditor; and approval of an amendment to the Certificate of Incorporation increasing authorized common shares from 300 million to 450 million. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-09
Item 1.01
Cheniere Partners closed a $1.75 billion private placement of senior notes ($1 billion 2036 Notes and $750 million 2056 Notes) on June 9, 2026. While this is a debt issuance rather than a traditional M&A transaction, Item 1.01 covers "Entry into a Material Definitive Agreement," and the closing of a material debt offering constitutes a significant financing event that would materially affect a reasonable investor's assessment of the company's capital structure and financial obligations. The substantial principal amounts and long maturities (10 and 30 years) make this material.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-09
Item 1.01
Novanta entered into a Securities Purchase Agreement for a private placement of approximately 2,142,857 common shares at $140.00 per share for approximately $300 million, representing approximately 6% dilution to existing shareholders. The unregistered equity sale under Section 4(a)(2) was announced with forward-looking statements regarding registration of the shares.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Talos Energy held its Annual Meeting of stockholders and disclosed voting results on four proposals: election of six director nominees, advisory approval of named executive officer compensation, approval of the Second Amended and Restated 2021 Long Term Incentive Plan (increasing shares by 4.5 million and extending the plan term), and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-09
Item 8.01
This disclosure reports the final receipt of $4.0 million from AstraZeneca as the second and final holdback under the Share Purchase Agreement for the sale of Kyntra Bio's China operations, which closed on August 29, 2025 for approximately $220 million in total consideration. The completion of all post-closing payments under a material acquisition/disposition agreement is a significant event affecting the company's cash position and the finalization of a major transaction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-09
Item 1.01
Nuburu entered into a binding Head of Terms with SunCubes S.r.l. on June 4, 2026, committing to a €1,000,000 investment for a minority stake in SunCubes and establishing an industrial cooperation framework for developing laser-arm systems. This constitutes a material acquisition activity under Item 1.01, involving capital commitment, equity acquisition, and strategic technology partnership that would materially affect investor assessment of the company's growth strategy and capital allocation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Axsome's 2026 Annual Meeting of Stockholders held on June 5, 2026. The filing presents voting outcomes for three proposals: election of two Class II directors (Mark Saad and Susan Mahony, Ph.D., MBA), ratification of Deloitte & Touche LLP as independent auditor, and non-binding advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-09
Item 5.02
The Compensation Committee approved adoption of a new Executive Severance and Change in Control Plan effective June 5, 2026, which establishes severance and change-in-control benefits for named executive officers and other key employees. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an executive departure or appointment. The plan specifies tiered severance payments, equity acceleration, and COBRA benefits triggered by qualifying termination events, making it material to investor assessment of executive compensation obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 35%
filed 2026-06-09
Item 8.01
MSD Investment Corp. priced a $300 million offering of 6.375% notes due 2029 in a private placement to qualified institutional buyers under Rule 144A and Regulation S. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, the event does not fit cleanly into the provided taxonomy. The "dilutive_issuance" category is defined as unregistered equity sales (private placements, PIPEs, convertible notes, ATM offerings), but this disclosure concerns debt notes, not equity. This is more accurately a debt financing event, which falls under "other_material" as it lacks a dedicated 8-K classification but materially affects the registrant's financial position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-09
Item 5.07
Enliven Therapeutics held its Annual Meeting of Stockholders on June 9, 2026, with voting results on five proposals: election of two Class III directors (Richard Fair and Lori Kunkel), ratification of Deloitte & Touche LLP as independent auditor, approval to increase authorized common shares from 100 million to 200 million, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-09
Item 5.02
Brian C. Thomas, Ph.D. resigned from his position as a member of the Board of Directors effective June 9, 2026, with the Company confirming the resignation was not due to disagreement.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Shareholders voted at the June 9, 2026 annual meeting to elect Juergen Eckhardt and Eric Bjerkholt as Class II Directors and to ratify PricewaterhouseCoopers LLP as the Company's independent auditor, with detailed voting tallies disclosed.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 96%
filed 2026-06-09
Item 5.02
Darlene Deptula-Hicks was appointed as a Class III director and Chair of the Audit Committee following the 2026 Annual Meeting of Shareholders held on June 9, 2026. The appointment was disclosed via press release and includes compensatory arrangements consisting of stock options and annual fees.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-09
Item 5.07
Shareholders voted at the 2026 Annual Meeting on June 9, 2026, approving three proposals: election of director Todd C. Brady, M.D., Ph.D. (23,026,101 votes for); ratification of BDO USA, P.C. as independent auditor (43,693,772 votes for); and advisory approval of named executive officer compensation (19,477,504 votes for). Vote counts, abstentions, and broker non-votes were disclosed for each proposal.
View raw filing on EDGAR →